

A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults with Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihistamines

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of Urticaria

Exclusion Criteria:

- prior use of remibrutinib, dupilumab or other BTK inhibitors

Conditions & Interventions

Interventions:

Drug: Dupilumab, Drug: Placebo solution for injection, Drug: Remibrutinib, Drug: Remibrutinib matching placebo

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

Chronic Spontaneous Urticaria

More Information

Description: The purpose of this study is to evaluate the efficacy of remibrutinib in comparison to dupilumab. We want to see which one works better for helping adults who have chronic spontaneous urticaria (CSU) and haven't had relief with use of second-generation antihistamines in treating adult participants who have CSU.

Study Contact: Melissa Kelly - kell2061@umn.edu

Principal Investigator: Paul Bigliardi

Phase: PHASE3

IRB Number: STUDY00025930

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.